Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADJORL1 adjuvant nivolumab ± ipilimumab after salvage surgery in HNSCC
2024-516810-39-00Phase 2Authorised
- Sponsor
- Gustave Roussy
- Start
- Feb 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of nivolumab and ipilimumab in head and neck squamous cell carcinoma (HNSCC) (4 cohorts), sponsored by Gustave Roussy. Primary endpoint: Two-year disease-free survival in cohorts 1 and 2. Planned start Feb 2018; status: authorised.
02
Drugs
nivolumabipilimumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2024-516810-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516810-39-00.